| Schedule of Segment Information |
The following table sets forth the Company’s segment information (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated |
|
|
Consolidated |
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Direct external expenses by program |
|
|
|
|
|
|
|
|
|
|
|
|
Zidesamtinib |
|
$ |
(16,665 |
) |
|
$ |
(18,141 |
) |
|
$ |
(49,496 |
) |
|
$ |
(43,393 |
) |
Neladalkib |
|
|
(30,047 |
) |
|
|
(20,770 |
) |
|
|
(86,352 |
) |
|
|
(44,697 |
) |
NVL-330 |
|
|
(6,173 |
) |
|
|
(1,541 |
) |
|
|
(16,062 |
) |
|
|
(5,251 |
) |
Discovery programs |
|
|
(3,293 |
) |
|
|
(2,086 |
) |
|
|
(8,842 |
) |
|
|
(6,636 |
) |
Personnel-related expenses (including stock-based compensation) |
|
|
(41,041 |
) |
|
|
(26,193 |
) |
|
|
(115,114 |
) |
|
|
(74,626 |
) |
General and administrative professional and consultant fees |
|
|
(4,020 |
) |
|
|
(3,058 |
) |
|
|
(9,963 |
) |
|
|
(7,735 |
) |
Change in fair value of related party revenue share liability |
|
|
(19,810 |
) |
|
|
(16,600 |
) |
|
|
(27,280 |
) |
|
|
(16,600 |
) |
Interest income |
|
|
10,203 |
|
|
|
8,652 |
|
|
|
33,156 |
|
|
|
25,297 |
|
Other segment items(1) |
|
|
(11,459 |
) |
|
|
(4,568 |
) |
|
|
(26,285 |
) |
|
|
(11,759 |
) |
Income tax provision |
|
|
(132 |
) |
|
|
(40 |
) |
|
|
(434 |
) |
|
|
(593 |
) |
Consolidated net loss |
|
$ |
(122,437 |
) |
|
$ |
(84,345 |
) |
|
$ |
(306,672 |
) |
|
$ |
(185,993 |
) |
(1) Other segment items included in consolidated net loss include expenses for commercialization preparation activities, information technology, research and development consulting services, employee recruitment, and other miscellaneous activities.
|